CN Patent

CN109689056A — 用于治疗癌症的组合

Assigned to Ignyta Inc · Expires 2019-04-26 · 7y expired

What this patent protects

本公开涉及用于治疗受试者的癌症的某些组合，所述组合包含Tyro3、Axl、Mer或c‑Met的一种或多种抑制剂，以及作为细胞毒性T淋巴细胞相关抗原4(CTLA‑4)的抑制剂的一种或多种化合物。

USPTO Abstract

本公开涉及用于治疗受试者的癌症的某些组合，所述组合包含Tyro3、Axl、Mer或c‑Met的一种或多种抑制剂，以及作为细胞毒性T淋巴细胞相关抗原4(CTLA‑4)的抑制剂的一种或多种化合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN109689056A
Jurisdiction
CN
Classification
—
Expires
2019-04-26
Drug substance claim
No
Drug product claim
No
Assignee
Ignyta Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.